



Published in final edited form as:

*Cell Microbiol.* 2012 January ; 14(1): 95–106. doi:10.1111/j.1462-5822.2011.01704.x.

## ***Pseudomonas aeruginosa* Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization**

**Meenu Mishra<sup>1,2,3</sup>, Matthew S. Byrd<sup>5</sup>, Susan Sergeant<sup>6,7</sup>, Abul K. Azad<sup>1,2,3</sup>, Matthew R. Parsek<sup>8</sup>, Linda McPhail<sup>6</sup>, Larry S. Schlesinger<sup>1,2,3,4</sup>, and Daniel J. Wozniak<sup>1,2,3,4,\*</sup>**

<sup>1</sup>Center for Microbial Interface Biology, The Ohio State University, Columbus, Ohio, USA

<sup>2</sup>Division of Infectious Diseases, The Ohio State University, Columbus, Ohio, USA

<sup>3</sup>Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA

<sup>4</sup>Department of Microbiology, The Ohio State University, Columbus, Ohio, USA

<sup>5</sup>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA

<sup>6</sup>Department of Biochemistry and Molecular Biology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA

<sup>7</sup>Wake Forest Center for Botanical Lipids and Inflammatory Disease Prevention, Wake Forest University Health Sciences, Winston-Salem, NC, USA

<sup>8</sup>Department of Microbiology, University of Washington, Seattle, WA, USA

### **Summary**

*Pseudomonas aeruginosa* causes chronic lung infections in the airways of cystic fibrosis (CF) patients. Psl is an extracellular polysaccharide expressed by non-mucoid *P. aeruginosa* strains, which are believed to be initial colonizers. We hypothesized that Psl protects *P. aeruginosa* from host defences within the CF lung prior to their conversion to the mucoid phenotype. We discovered that serum opsonization significantly increased the production of reactive oxygen species (ROS) by neutrophils exposed to a *psl*-deficient mutant, compared with wild-type (WT) and Psl overexpressing strains (Psl<sup>++</sup>). Psl-deficient *P. aeruginosa* were internalized and killed by neutrophils and macrophages more efficiently than WT and Psl<sup>++</sup> variants. Deposition of complement components C3, C5 and C7 was significantly higher on *psl*-deficient strains compared with WT and Psl<sup>++</sup> bacteria. In an *in vivo* pulmonary competition assay, there was a 4.5-fold fitness advantage for WT over *psl*-deficient *P. aeruginosa*. Together, these data show that Psl inhibits efficient opsonization, resulting in reduced neutrophil ROS production, and decreased killing by phagocytes. This provides a survival advantage *in vivo*. Since phagocytes are critical in

© 2011 Blackwell Publishing Ltd

\*For correspondence. daniel.wozniak@osumc.edu; Tel. (+1) 614 247 7629; Fax (+1) 614 292 9616.

### **Supporting information**

Additional Supporting Information may be found in the online version of this article:

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

early recognition and control of infection, therapies aimed at Psl could improve the quality of life for patients colonized with *P. aeruginosa*.

---

## Introduction

*Pseudomonas aeruginosa* is a versatile opportunistic pathogen that can cause chronic pulmonary infection in cystic fibrosis (CF) patients and is also a significant cause of disease in immune-compromised patients (Lyczak *et al.*, 2002). The ability of *P. aeruginosa* to form biofilms that are recalcitrant to treatment is a major cause of mortality and morbidity in these patients. Neutrophils are the first phagocytic cells mobilized to clear pathogenic bacteria during lung infection, yet pulmonary infection in CF is complicated by the robust recruitment, activation and damage caused by these cells (Walker *et al.*, 2005). During colonization and infection of the CF airway, *P. aeruginosa* undergoes phenotypic conversion from a non-mucoid to mucoid morphology. This phenotype is due to the overproduction of alginate, a capsular polysaccharide that confers a selective advantage for *P. aeruginosa*. Alginate produced by mucoid *P. aeruginosa* scavenges bactericidal reactive oxygen species (ROS), and interferes with complement activation, chemotaxis, and neutrophil and macrophage phagocytic killing (Learn *et al.*, 1987; Pedersen *et al.*, 1990; Mai *et al.*, 1993; Leid *et al.*, 2005). However, in most CF patients, mucoid conversion occurs months or years after initial colonization (Govan and Deretic, 1996). There remain significant gaps in our understanding of how *P. aeruginosa* survives the inflammatory-rich environment of the CF lung prior to converting to the alginate-producing phenotype.

Psl is a recently discovered exopolysaccharide (EPS) of non-mucoid *P. aeruginosa* and the genes encoding this EPS are highly conserved among *P. aeruginosa* isolates (Wolfgang *et al.*, 2003). Psl is composed of repeating pentasaccharide units of D-mannose, D-glucose and L-rhamnose (Byrd *et al.*, 2009). Psl is critical for biofilm formation and believed to be expressed in *P. aeruginosa* isolates that are the first to colonize CF patients (Jackson *et al.*, 2004; Ma *et al.*, 2006). This implies that during initial infection, biofilm formation and Psl synthesis likely precede the switch to mucoidy. Polysaccharides in several pathogenic bacteria can promote phagocyte evasion by modulating deposition of complement or antibody on the microbe's surface (Clay *et al.*, 2008; Goebel *et al.*, 2008). However, there have been no studies investigating if *P. aeruginosa* Psl modulates interactions with cells of the innate immune system.

We focused our study on neutrophils and complement since these innate immune effectors are critical in host defence against *P. aeruginosa* (Jesaitis *et al.*, 2003; Mueller-Ortiz *et al.*, 2004). Neutrophils are recruited early in infection and directly kill invading bacteria using both oxidative and non-oxidative mechanisms. The complement system is a highly regulated and multifunctional pathway that promotes recognition of pathogens by innate immune cells and is also capable of direct bacterial killing upon insertion of the terminal membrane attack complex (MAC). Opsonization by complement is a central mechanism for bacterial clearance and is crucial for maintaining mucosal immunity against infection (Gross *et al.*, 1978). Once bacteria are taken up by neutrophils, the subsequent oxidative burst leads to the production of toxic ROS (Kanegasaki, 1986; Nauseef, 2007). The processes of

degranulation, phagocytosis and oxidative killing furnish the neutrophil with a varied arsenal of antimicrobial effectors that are critical for an effective innate immune response.

A central hypothesis in the present study is that surface-bound Psl impairs phagocytosis by reducing complement-mediated opsonization. To test this, we utilized a collection of isogenic *P. aeruginosa* strains expressing variable amounts of surface Psl polysaccharide. Compared with WT bacteria, *P. aeruginosa* lacking Psl demonstrated increased complement-mediated opsonization. Lack of Psl expression led to enhanced uptake, oxidative burst response, and reduced intracellular bacterial survival in phagocytic cells. The presence of Psl provided *P. aeruginosa* a fitness advantage over *psl* mutants in an acute murine pulmonary model of infection. Enzymatic degradation of surface Psl also resulted in increased complement deposition, suggesting that pharmacological agents aimed at reducing Psl levels may enhance recognition and clearance of *P. aeruginosa* by innate immune effectors.

## Results

### Both serum opsonins and Psl polysaccharide affect the oxidative burst response generated by human neutrophils

To determine if Psl affects the oxidative burst response generated by human neutrophils, we used three isogenic *P. aeruginosa* strains previously developed (Ma *et al.*, 2006) including WFPA801, an inducible Psl overexpressing variant, the *psl*-deficient strain WFPA800, and WT strain PAO1. Psl expression by these strains was verified with an immunoblot of surface extracted polysaccharide (Fig. 1A). To measure the oxidative burst response generated by human neutrophils towards these *P. aeruginosa* strains, we incubated fresh serum-opsonized bacteria with human neutrophils in the presence of luminol and monitored the oxidative burst over time (Fig. 1B). Luminol is known to react with both extra- and intracellular superoxide anions generated by neutrophils (Briheim *et al.*, 1984). Kinetic analyses of neutrophils exposed to serum-opsonized *psl* mutants showed a more rapid and robust oxidative burst response compared with neutrophils incubated with equivalent numbers of WT or Psl overexpressing strains (Fig. 1B). The highest oxidative burst response was observed at 25 min. Therefore, this time point was chosen for comparing the response of neutrophils exposed to bacteria under serum-opsonized (NHS), unopsonized and heat-inactivated serum (HIS) opsonized conditions (Fig. 1C). The oxidative burst response of neutrophils exposed to serum-opsonized WT, *psl* mutant and a Psl overexpressing *P. aeruginosa* strain was significantly higher compared with non-opsonized strains (Fig. 1C). Furthermore, there was a significant reduction but not elimination of the oxidative burst response generated by neutrophils incubated with *P. aeruginosa* opsonized with HIS, which is devoid of complement activity (Fig. 1C). These studies were also performed utilizing the fluorescence probe dichlorohydro-fluorescein (DCF) to detect ROS and similar results were observed (data not shown). This suggests that serum opsonins (both complement and immunoglobulin) and the Psl status significantly affect the activity of neutrophils, which are critical in the innate immune responses towards *P. aeruginosa*. The remainder of this study focused only on the contribution of complement as the opsonin.

We previously showed that some Psl is released from cells during growth of *P. aeruginosa* (Byrd *et al.*, 2009). One potential explanation for the results in Fig. 1 is that released Psl may be directly inhibiting the oxidative burst of neutrophils. This is the case for EPS produced by *Burkholderia cenocepacia* (Bylund *et al.*, 2006). However, there was no significant difference in the oxidative burst response of neutrophils stimulated with phorbol myristate acetate (PMA) either in the presence or absence of purified Psl (Fig. S1). This suggests that Psl is not sufficient to inhibit neutrophil activation.

### **The presence of Psl reduces opsonophagocytosis of *P. aeruginosa* by human innate immune cells**

As outlined in Fig. 1, the presence of Psl limits the oxidative burst response by neutrophils. We reasoned that these differential burst responses might be due to differences in the phagocytosis of *P. aeruginosa* strains. To evaluate this, serum opsonized *P. aeruginosa* WT and *psl*-deficient strains were incubated with human neutrophils and THP-1 derived macrophages. THP-1 macrophages have been frequently used to study bacterial internalization (Longhi *et al.*, 2004; Ferrer *et al.*, 2010). Unattached bacteria were removed by washing extensively and bacterial association and internalization assessed by differential immunofluorescence staining (see *Experimental procedures*). The amount of *psl*-defective bacteria taken up by THP-1 macrophages was 4.5-fold higher compared with that of the WT strain (Fig. 2A). In human neutrophils, there was an approximately threefold higher number of *psl*-deficient *P. aeruginosa* internalized when compared with WT bacteria (Fig. 2B). Thus, the increased phagocytosis of the *psl*-deficient strain correlates well with the increased oxidative burst observed when neutrophils are exposed to the same mutant strain.

### **The presence of Psl inhibits deposition of complement component C3, C5 and C7 on the *P. aeruginosa* surface**

The activation of complement can cause direct lysis of bacteria or increase opsonophagocytosis (Pangburn and Muller-Eberhard, 1980; van Lookeren Campagne *et al.*, 2007; Clay *et al.*, 2008). Data in Fig. 1C show that opsonization of *P. aeruginosa* with heat-inactivated human serum reduced the oxidative burst response relative to fresh human serum, indicating a significant contribution of complement in the recognition of *P. aeruginosa* bacteria by neutrophils. We subsequently evaluated the effect of Psl on deposition of complement component C3, which promotes opsonization and is central to all three complement cascade pathways (Pangburn and Muller-Eberhard, 1980). *P. aeruginosa* strains were opsonized and C3 deposition was evaluated by flow cytometry. There was a significant increase in C3 deposition on *psl*-deficient *P. aeruginosa* compared with WT and Psl overexpressing strains (Fig. 3A). Following a 5 min opsonization period, C3 complement deposition on *psl*-deficient *P. aeruginosa* was increased  $2.1 \pm 0.34$ - and  $4.1 \pm 0.28$ -fold, compared with WT and Psl overexpressing bacteria respectively. C3 deposition on *psl*-deficient *P. aeruginosa* was also significantly higher compared with WT and Psl overexpressing *P. aeruginosa* after 20 min of opsonization (Fig. 3A).

We confirmed enhanced C3 deposition on serum opsonized *psl*-deficient *P. aeruginosa* compared with WT strains using immunogold transmission electron microscopy (TEM).

These data also revealed C3 deposition on the *psl*-deficient *P. aeruginosa* surface was elevated threefold compared with C3 binding to WT bacteria (Fig. 3B).

While one role of complement is to facilitate opsonophagocytosis, complement components also can directly kill bacteria through generation of the membrane attack complex (MAC), which requires complement components C5-C9. To examine the effect of Psl on complement components associated with the terminal lytic pathway, C5 and C7 deposition was evaluated. When opsonized for 20 min, C5 and C7 deposition was significantly higher on *psl*-deficient *P. aeruginosa* compared with WT and Psl over-expressing strains (Fig. 4A and B respectively). Increased C5 deposition occurred as early as 5 min, similar to the results with C3 and thus highlighting the rapid kinetics of complement activation on the *psl*-deficient strain. C7 deposition was somewhat delayed (Fig. 4B). Since complement deposition occurs sequentially, the observed increase in C5 and C7 binding on Psl-deficient *P. aeruginosa* (Fig. 4A and B) is likely due to the fact that C3 deposition was elevated on these bacteria.

We next examined the binding of C9 to *P. aeruginosa* strains. Although C5b, C6, C7, C8 and C9 are necessary for forming the MAC complex, the multimeric form of C9 is involved in the actual disruption of the phospholipid membrane (Inoue and Yonemasu, 1968; Goldman *et al.*, 1969; Schreiber *et al.*, 1979; Joiner *et al.*, 1985). In contrast to C3, C5 and C7 deposition, we found little difference in the amount of C9 bound to *P. aeruginosa* WT, *psl*-deficient, or Psl overexpressing strains (Fig. 5A), suggesting that differences observed in upstream complement components do not translate into increased C9 deposition on *psl*-deficient cells.

C9 assembly on the surface of bacteria is essential for MAC formation and serum-mediated killing (Joiner *et al.*, 1985). To test whether the presence of Psl affected serum-mediated killing, a bacterial survival assay was performed in the presence of fresh human serum. We also included an LPS O-antigen-deficient *P. aeruginosa* strain (*waaL*) as a control since an intact O-antigen is necessary for serum resistance (Hancock *et al.*, 1983). Addition of normal human serum at two concentrations (20% and 50%) failed to kill WT or any of the Psl variant strains (Fig. 5B). As expected, *P. aeruginosa waaL* was more serum sensitive than the parental strain. These results indicate little role for Psl in promoting serum resistance.

### **Disruption of Psl by addition of exogenous cellulase increases C3 complement binding on the bacterial surface**

Since *psl* mutants are more efficiently opsonized and taken up by phagocytes than are WT *P. aeruginosa*, agents aimed at removal of Psl may promote clearance of these bacteria during infection. As a proof of principle we utilized cellulase, which disrupts  $\beta$ 1-3 and  $\beta$ 1-4 linkages in Psl (Ma *et al.*, 2009), and examined the effect on C3 binding. Bacteria were left untreated or treated with cellulase, extensively washed, opsonized and C3 binding examined (see *Experimental procedures*). When opsonized for 5 min, cellulase-treated WT bacteria exhibited a 10-fold increase in C3 binding on the surface compared with untreated cells. WT *P. aeruginosa* treated with phosphate-buffered saline (PBS) or PBS + cellulase showed  $6.31 \pm 2.58\%$  and  $66.78 \pm 0.66\%$  C3 complement deposition respectively. This effect was

reduced but still significant with longer opsonization times, indicating that either cellulase did not remove all Psl or that C3 binding at later time points becomes saturated. Importantly, treatment of the *psl*-deficient strain with cellulase did not further increase C3 binding (*psl* with PBS or PBS + cellulase showed  $58.49 \pm 12\%$  and  $69.57 \pm 2.7\%$  C3 deposition respectively). This suggests that Psl is the primary cell surface molecule targeted by cellulase.

### **Psl promotes the intracellular survival of *P. aeruginosa***

To study the role of Psl in protection of bacteria from neutrophil killing, we incubated normal serum opsonized WT and *psl*-deficient strains of *P. aeruginosa* with human neutrophils and performed a gentamicin survival assay (see *Experimental procedures*). Compared with the WT and Psl overexpressing strains, there was an eightfold reduction in intracellular survival of *psl* mutants (Fig. 6A). We reasoned that this reduced survival of *psl* mutants in neutrophils was likely due to their increased opsonophagocytosis, and more intense oxidative burst compared with that generated in response to WT bacteria. To address any potential additional role for Psl in protection from intracellular killing by neutrophils, we normalized the bacterial uptake in neutrophils by adjusting the multiplicity of infection (moi) of WT and *psl*-deficient *P. aeruginosa* and repeated the intracellular killing assay as above. Under these conditions, equivalent numbers of WT and *psl* mutant bacteria were taken up by neutrophils (Fig. 6B). Our result revealed that WT *P. aeruginosa* bacteria had a sixfold increase in survival compared with the *psl*-deficient strain (Fig. 6A). These data indicate an additional role for Psl in providing protection of bacteria from intracellular neutrophil-mediated killing.

### **The presence of Psl provides a fitness advantage for *P. aeruginosa* during an acute murine pulmonary infection**

Since Psl appears to limit opsonophagocytosis and promotes intracellular survival in neutrophils, we designed a study to determine if WT *P. aeruginosa* had an *in vivo* fitness advantage compared with a *psl*-deficient strain. Mice were co-infected intranasally with a 1:1 mixture of isogenic WT and *psl*-deficient strains of *P. aeruginosa*. These bacteria were distinguished based on differential antibiotic susceptibility (see *Experimental procedures*). At 4 and 12 h post infection mice were sacrificed and the bacterial burden was enumerated from the lung homogenate. The mean competitive index (CI) value was 1.2 at 4 h post infection, indicating similar delivery of both WT and *psl* mutants. However, this declined to 0.3 at 12 h post infection, indicating that *psl*-deficient bacteria had a significantly reduced fitness advantage in the lungs of mice when co-infected with WT strains. An *in vitro* growth competition experiment with co-culturing PAO1 Sm<sup>r</sup> and *psl*-deficient bacteria did not show a growth advantage for either strain with a CI value of 1.0. These results support the conclusion that Psl contributes to protection of *P. aeruginosa* from innate immune cells.

## **Discussion**

Psl polysaccharide plays a crucial role in initial attachment and biofilm formation by non-mucoid *P. aeruginosa* strains (Friedman and Kolter, 2004; Jackson *et al.*, 2004; Matsukawa and Greenberg, 2004). Non-mucoid, Psl-expressing bacteria are believed to be the first to

colonize the CF airway and are challenged with a harsh inflammatory- and neutrophil-rich lung environment. There have been no studies addressing the potential role of EPS expressed by non-mucoid *P. aeruginosa* in protecting bacteria from the phagocytic activity of neutrophils or other effectors of innate immunity. In this study we show that (i) serum opsonins (both complement and immunoglobulin) and the Psl status are critical components in dictating the host innate immune response towards non-mucoid *P. aeruginosa*; (ii) the presence of Psl reduces opsonophagocytosis of *P. aeruginosa* by human innate immune cells; (iii) Psl inhibits deposition of complement component C3, C5 and C7 on the *P. aeruginosa* surface; (iv) disruption of Psl by addition of exogenous cellulase increases C3 complement binding on the bacterial surface; (v) Psl promotes the intracellular survival of *P. aeruginosa*; and (vi) Psl-proficient bacteria have a competitive advantage over Psl-deficient strains *in vivo*.

Phagocytosis by innate immune cells is a multi-step process, which involves microbe recognition and ingestion by neutrophils and subsequent degradation by generating ROS and other digestive enzymes. The sequential production of ROS due to bacterial and neutrophil interaction is collectively known as an oxidative burst (Lorenzen *et al.*, 2000; Roos *et al.*, 2003; Nauseef, 2007). Bacterial polysaccharides produced by *B. cenocepacia* and *Staphylococcus aureus* also prevent phagocytosis and killing by immune cells (Karakawa *et al.*, 1988; Thakker *et al.*, 1998; Kampen *et al.*, 2005; Saldias *et al.*, 2009). Our data clearly demonstrate that Psl reduces bacterial uptake and the oxidative burst response generated by neutrophils when challenged with opsonized *P. aeruginosa*. We also observed an enhanced oxidative burst response to non-opsonized Psl overexpressing strains compared with that of non-opsonized WT *P. aeruginosa* (Fig. 1C). This might be due to an interaction of Psl with non-opsonic receptors on neutrophils. Mannose receptors of monocyte-derived macrophages facilitate phagocytosis of non-opsonized *P. aeruginosa* (Speert *et al.*, 1988), and Psl is mannose-rich (Byrd *et al.*, 2009). Heale *et al.* also suggested independent involvement of CR3 or CD14 in non-opsonic phagocytosis of *P. aeruginosa* strains (Heale *et al.*, 2001). Importantly, purified Psl exhibited no effect on PMA induced neutrophil burst responses *in vitro*, indicating that Psl does not likely directly inhibit neutrophil function.

Gondwe *et al.* showed the importance of opsonins for induction of the oxidative burst response of neutrophils and monocytes by invasive non-typhoidal *Salmonella* (Gondwe *et al.*, 2010). Similarly, *P. aeruginosa* opsonization clearly affects the response of neutrophils (Fig. 1C). The results in Figs 3 and 4 also provide an explanation for the data in Fig. 1, since elevated opsonization of the *psl* mutants is expected to enhance opsonophagocytosis with a resultant increase in the oxidative burst response. Opsonization of bacteria requires deposition of activated C3b on the surface. C3b forms stable thioester bonds, leading to the covalent attachment of C3b with free hydroxyl or amine groups present on the surface of bacteria (Abdul Ajees *et al.*, 2006). We currently favour the hypothesis that Psl functions by masking the accessibility of a ligand(s) present on the bacterial surface for interaction with C3. The identity of the *P. aeruginosa* surface ligand(s) to which C3 binds is not known.

Our observation that WT and *psl*-deficient *P. aeruginosa* show differential C3 deposition when incubated with human serum is similar to the findings of Clay *et al.* (2008). Their data provided evidence that the LPS O-antigen regulates complement C3 deposition on the

surface of *Francisella tularensis* and is a major determinant of complement activation. A role of O-antigen in preventing C3 deposition on *Bordetella parapertussis* has also been established (Goebel *et al.*, 2008). Given the importance of C3 in host defence (Clay *et al.*, 2008; Barker *et al.*, 2009), the inhibitory role of Psl for C3 deposition on the bacterial surface may provide additional protection of the pathogen in the environment of the CF lung and could help promote a chronic infection.

In contrast to other polysaccharides, i.e. *Escherichia coli* K2 capsule and the O-antigen of *F. tularensis*, which contribute to serum resistance (Clay *et al.*, 2008; Buckles *et al.*, 2009), Psl EPS does not appear to protect *P. aeruginosa* against complement-mediated killing. This could be due to several reasons. Bacterial killing by complement is associated with partial or complete dissolution of the outer membrane, and the molecular form of the C5-9 complex is crucial for optimal killing (Feingold *et al.*, 1968a,b). Joiner *et al.* confirmed that multimeric C9 is necessary for *E. coli* J5 killing and that sufficient polymerization of C9 rendered disruption of the multilamellar detergent resistant bacterial cell wall (Joiner *et al.*, 1985). An average of at least three C9 molecules is required for one C5-8 complex to kill susceptible cells (Joiner *et al.*, 1985; Bloch *et al.*, 1987). *Trypanosoma cruzi* amastigotes escape complement mediated killing because C9, while bound efficiently, is not inserted deep enough in the parasite lipid bilayer and fails to form pores in the membrane (Iida *et al.*, 1989). Therefore, the correct stoichiometric ratio of MAC complement components may be suboptimal for lysis of both WT and Psl-defective *P. aeruginosa*. Alternatively, one or more molecules on the bacterial surface might be inhibiting the polymerization of C9 resulting in protection from serum killing. Multiple factors likely contribute to preventing the effect of MAC-mediated killing of *P. aeruginosa*. While our results do not support a role for Psl in protection against complement-mediated killing, it is intriguing that there were significant differences in deposition of C3, C5 and C7 complement components on the surface of WT versus *psl* mutants. The observation that there were no apparent differences in C9 binding among the strains could be explained by the fact that multiple copies of C9 are normally found in the MAC (Kolb *et al.*, 1972; Kondos *et al.*, 2010), and the sensitivity of our binding assays may not be sufficient to resolve such differences.

Since our data suggested a protective role for Psl during interactions with neutrophils *in vitro*, we performed an *in vivo* acute murine pulmonary infection experiment. These results also revealed that Psl provides a fitness advantage to *P. aeruginosa* *in vivo* (Fig. 7). To our knowledge, this is a first study that addresses the impact of Psl during interaction with cells of the innate immune system *in vivo* and *in vitro*.

In conclusion, our results demonstrate that deletion of Psl leads to increased complement deposition on the bacterial surface and increased opsonophagocytosis, oxidative burst, and bacterial killing by neutrophils. Complement components play an important role in the recognition and clearance of bacteria by facilitating phagocytosis by innate immune cells. Using a murine model of pneumonia, Stacey *et al.* showed that C3 deficient mice had more robust *P. aeruginosa* colonization compared with wild-type mice (Mueller-Ortiz *et al.*, 2004). The reduction of CI at 12 h post infection in our *in vivo* model could suggest that Psl is important for adaptation to host conditions that exist later in infection. This may be one mechanism by which non-mucoid *P. aeruginosa* persists during lung infection in CF



patients even in the presence of a robust neutrophil response (Fig. 7). The *psl* operon appears to be highly conserved in clinical and environmental isolates of *P. aeruginosa* (Wolfgang *et al.*, 2003; Jackson *et al.*, 2004). Given the importance of Psl in colonization, biofilm formation and avoidance of host defence mechanisms, Psl may represent a therapeutic target for prevention of persistent *P. aeruginosa* infection in CF patients.

## Experimental procedures

### Strains and growth media

Wild-type *P. aeruginosa* (PAO1), Psl-deficient *P. aeruginosa* WFPA800 (*psl*), the arabinose-inducible Psl overexpressing strain WFPA801 (Ma *et al.*, 2006), a streptomycin resistant variant of PAO1 (Jackson *et al.*, 2004), and the O-antigen deficient strain of *P. aeruginosa* (*waaL*) (Abeyrathne *et al.*, 2005), were grown in Luria–Bertani (LB) without NaCl (LBNS). Arabinose was added to WFPA801 for induction of Psl (2% w/v final concentration) and also included in the WT (PAO1) and Psl-deficient (WFPA800) culture as a control. No antibiotic selection was used for routine growth of these strains.

### Neutrophil isolation and oxidative burst studies

Human neutrophils and serum were obtained from healthy adult donors using an approved IRB protocol (2009H0314) at The Ohio State University. Heparinized blood was placed on a Ficoll Hypaque density cushion (Amersham Biosciences), centrifuged at 400 *g* and the resultant RBC-rich pellet was resuspended 1:1 in normal saline. To obtain a leucocyte-rich supernatant, RBCs were allowed to sediment in the presence of 1.5% dextran at 4°C for 30 min. The supernatant was gently removed and centrifuged at 550 *g* for 10 min at 4°C. Pelleted RBCs were subjected to hypotonic lysis with 10 ml of distilled water and the isotonicity was restored by the addition of an equal amount of 1.8% NaCl. Neutrophils were resuspended in Hank's buffered salt solution (HBSS), counted on a haemocytometer, and kept on ice for use.

The luminol chemiluminescence assay was used to detect intracellular and extracellular ROS generated by neutrophils upon interaction with *P. aeruginosa* (Engels *et al.*, 1985). WT *P. aeruginosa*, *psl* and Psl-overexpressing bacterial suspensions were opsonized with 10% fresh human serum at 37°C for 30 min, washed and compared for generation of the ROS response by neutrophils. PMA (10 ng) was used as a positive control for generation of the ROS by neutrophils. Neutrophils ( $2 \times 10^5$ ) were seeded on a 96-well microtitre plate and a bacterial suspension of mid-log phase culture was added (moi of 50 bacteria to 1 neutrophil) to the wells in the presence of 50  $\mu$ M of luminol. The microtitre plate was centrifuged at 100 *g* for 2 min at 12°C to synchronize the infection. The relative amount of ROS generated by neutrophils was detected at regular intervals over 72 min by measuring the luminescence. Relative light units (RLU) were plotted as a function of time to evaluate chemiluminescence (CL) rate (Mohapatra *et al.*, 2010). The DCF assay for detecting the respiratory burst was performed as outlined elsewhere (Crowther *et al.*, 2004). Psl was purified according to Byrd *et al.* (2009) and 500  $\mu$ g or 1 mg was used to study the oxidative burst response by PMA-activated neutrophils.

### Complement component deposition and bacterial killing

Methods by Balagopal *et al.* (2006) were used to harvest fresh complement sufficient serum. Mid-log phase grown bacteria were opsonized with 20% fresh human serum at 37°C for 5 and 20 min, and reactions stopped by the addition of 10 mM EDTA and incubation on ice. Bacteria were washed, fixed and stained using anti-human C3 (Quidel), C5, C7 or C9 polyclonal antibodies (Complement Tech.) at a 1:1000 dilution. Following incubation, samples were washed and detected using Alexa Fluor 647-conjugated secondary antibody (Invitrogen) at a 1:500 dilution. After final washes, the pelleted bacteria were analysed by flow cytometry (FACS Calibur; BD Biosciences) for quantification of complement deposition on the bacterial surface. Non-opsonized bacteria were used in each experiment to set the gate for analysis. Data from 30 000-gated events were collected and the percentage of fluorescence (percentage positive cells) was calculated for each sample. For the bacterial killing assays, mid-log phase WT, *psl*, Psl-overexpressing and *waaL* strains of *P. aeruginosa* were opsonized with PBS or 20% and 50% pooled normal human serum (Complement Tech.) for 30 min at 37°C with slow agitation. The tubes were placed on ice for 5 min to stop the reaction, bacteria were washed extensively, and 10-fold serial dilutions were plated to determine surviving colony-forming units (cfu).

### Electron microscopy

Mid-log phase grown bacteria were opsonized with 20% pooled human serum (Complement Tech.) at 37°C for 20 min. Reactions were stopped by adding 10 mM EDTA, bacteria were washed, fixed, blocked and stained with anti-human C3 antibody (1:500 dilution) for 1 h. Following incubation, samples were washed and counter stained with 15 nm colloidal gold labelled rabbit anti-goat antibody (Abcam) at a dilution of 1:500 for 1 h. Labelled samples were washed, fixed and embedded in Eponate 12 resin, followed by sectioned on a Leica EMU 6 ultramicrotome. Sections were collected onto grids and viewed by transmission electron microscopy (FEI Tecnai G2 Spirit) operating at 80 kV. Images in Fig. 3B are representative of cells in two independent experiments. For quantification of C3 binding, 100 random bacterial cells were evaluated in two independent experiments.

### Bacterial uptake by neutrophils

Neutrophils ( $2 \times 10^5$  per well) were seeded on poly-L-lysine coated coverslips and mid-log phase *P. aeruginosa*, opsonized with 20% human serum, were added at an moi (bacteria : neutrophil) of 10:1, 5:1 and 3:1 onto the neutrophil monolayers in the appropriate experiment. The mixture was incubated for 30 min at 37°C, 5% CO<sub>2</sub>. Cells were washed extensively with HBSS to remove non-adherent bacteria, fixed and stained with anti-*Pseudomonas* antibody (diluted to 1:1000) before and after cell membrane permeabilization with methanol (Balagopal *et al.*, 2006). The anti-*Pseudomonas* antibody was generated against whole surface antigens of strain PAO1. Visualization of bacteria-phagocyte association by confocal microscopy (Olympus FV 1000) using 60× oil objective allowed us to differentiate attached *P. aeruginosa* from internalized bacteria. Attached bacteria exposed to the antibodies before permeabilization stain green due to counter staining with Alexa Fluor 488 (diluted to 1:500), while internalized bacteria exposed to the antibodies after permeabilization stain red due to Alexa Fluor 647 as a secondary stain (diluted to 1:500).

For quantification, 100 neutrophils were chosen at random and the cell-associated versus internalized bacteria counted and averaged by two readers blinded to the treatment conditions. Bacterial uptake was also studied in THP-1-derived macrophages by growing THP-1 cells in RPMI supplemented with 10% FBS. Cultured THP-1 cells were stimulated with 100 nM PMA for 36 h prior to the addition of bacterial suspension. The resultant THP-1 derived macrophages were incubated with bacteria for 90 min and bacterial attachment and internalization were analysed as above.

### ***P. aeruginosa*-neutrophil killing assay**

Neutrophils ( $2 \times 10^5$ ) were seeded onto poly-L-lysine coated 24-well plates in HBSS, and mid-log phase cultures of bacteria were added at an moi of 100:1. To normalize the uptake of bacteria by neutrophil, this experiment was also performed with reduced moi of *psl*-deficient *P. aeruginosa* (30:1). After a 30 min incubation, neutrophils were washed vigorously and treated with  $150 \mu\text{g ml}^{-1}$  gentamicin for 30 min at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  to kill extracellular and attached bacteria. Samples were washed and lysed with 0.1% Triton X-100 for 2 min immediately prior to plating for cfu. The percentage of killed bacteria was calculated relative to the total number of cell-associated bacteria. To estimate the total number of associated bacteria, wells were not treated with gentamicin.

### **Cellulase treatment**

Mid-log phase bacteria were incubated with  $10 \text{ mg ml}^{-1}$  cellulase (1.38 unit per mg, Sigma) in PBS for 20 h at  $37^\circ\text{C}$ . After extensive washing with PBS bacteria were opsonized with 20% normal human pooled serum and C3 deposition on the bacterial surface was evaluated at both 5 min and 30 min time points as above.

### ***In vivo* mixed infection competition**

All experimental animals were handled in accordance with OSU institutional guidelines (IACUC approval number 2009A0177). *P. aeruginosa* strains grown to  $\text{OD}_{600} = 0.5$  at  $37^\circ\text{C}$ , harvested by centrifugation, washed with PBS, and diluted to an estimated concentration of  $1 \times 10^8$  bacteria in  $30 \mu\text{l}$ . Groups of 5 female C57BL/6 mice were mildly sedated by isoflurane inhalation and infected intranasally with  $\sim 1 \times 10^8$  total bacteria of a 1:1 mixture of streptomycin resistant *P. aeruginosa* PAO1 and its isogenic *psl*-deficient strain. A parallel control group received the same inoculum of PBS. At 4 and 12 h post infection, five mice from each group were euthanized and lung homogenates plated in the presence and absence of streptomycin for differential enumeration of bacterial strains. The CI was calculated by dividing the ratio of the amount of *psl*-deficient bacteria recovered by the amount of PAO1  $\text{Sm}^r$  recovered (CI values  $< 1$  indicate a competitive advantage of the WT strain). An *in vitro* growth competition experiment with co-culturing PAO1  $\text{Sm}^r$  and WFPA800 did not show a growth advantage for either strain or a CI value of 1.0.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by Public Health Service grants AI061396 and HL058334 (D.J.W.), a WFUHS intramural grant to L.C.M., CFF fellowship MISHRA11F0 (M.M.), and NRSA fellowship AI07870002 (M.S.B.). We would like to acknowledge Richard Montione from the Campus Microscopy and Imaging Facility of the Ohio State University for excellent technical help with TEM. We thank Preston Hill for the preparation of Psl, and Dominique Limoli, Christopher Jones and Kurtis Host for providing assistance with the animal experiments.

## References

- Abdul Ajees A, Gunasekaran K, Volanakis JE, Narayana SV, Kotwal GJ, Murthy HM. The structure of complement C3b provides insights into complement activation and regulation. *Nature*. 2006; 444:221–225. [PubMed: 17051152]
- Abeyrathne PD, Daniels C, Poon KK, Matewish MJ, Lam JS. Functional characterization of WaaL, a ligase associated with linking O-antigen polysaccharide to the core of *Pseudomonas aeruginosa* lipopolysaccharide. *J Bacteriol*. 2005; 187:3002–3012. [PubMed: 15838026]
- Balagopal A, MacFarlane AS, Mohapatra N, Soni S, Gunn JS, Schlesinger LS. Characterization of the receptor-ligand pathways important for entry and survival of *Francisella tularensis* in human macrophages. *Infect Immun*. 2006; 74:5114–5125. [PubMed: 16926403]
- Barker JH, McCaffrey RL, Baman NK, Allen LA, Weiss JP, Nauseef WM. The role of complement opsonization in interactions between *F. tularensis* subsp. *novicida* and human neutrophils. *Microbes Infect*. 2009; 11:762–769. [PubMed: 19409509]
- Bloch EF, Schmetz MA, Foulds J, Hammer CH, Frank MM, Joiner KA. Multimeric C9 within C5b-9 is required for inner membrane damage to *Escherichia coli* J5 during complement killing. *J Immunol*. 1987; 138:842–848. [PubMed: 3100618]
- Briheim G, Stendahl O, Dahlgren C. Intra- and extracellular events in luminol-dependent chemiluminescence of polymorphonuclear leukocytes. *Infect Immun*. 1984; 45:1–5. [PubMed: 6329953]
- Buckles EL, Wang X, Lane MC, Lockett CV, Johnson DE, Rasko DA, et al. Role of the K2 capsule in *Escherichia coli* urinary tract infection and serum resistance. *J Infect Dis*. 2009; 199:1689–1697. [PubMed: 19432551]
- Bylund J, Burgess LA, Cescutti P, Ernst RK, Speert DP. Exopolysaccharides from *Burkholderia cenocepacia* inhibit neutrophil chemotaxis and scavenge reactive oxygen species. *J Biol Chem*. 2006; 281:2526–2532. [PubMed: 16316987]
- Byrd MS, Sadovskaya I, Vinogradov E, Lu H, Sprinkle AB, Richardson SH, et al. Genetic and biochemical analyses of the *Pseudomonas aeruginosa* Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. *Mol Microbiol*. 2009; 73:622–638. [PubMed: 19659934]
- Clay CD, Soni S, Gunn JS, Schlesinger LS. Evasion of complement-mediated lysis and complement C3 deposition are regulated by *Francisellatularensis* lipopolysaccharide O antigen. *J Immunol*. 2008; 181:5568–5578. [PubMed: 18832715]
- Crowther JE, Kutala VK, Kuppusamy P, Ferguson JS, Beharka AA, Zweier JL, et al. Pulmonary surfactant protein a inhibits macrophage reactive oxygen intermediate production in response to stimuli by reducing NADPH oxidase activity. *J Immunol*. 2004; 172:6866–6874. [PubMed: 15153505]
- Engels W, Endert J, Kamps MA, van Boven CP. Role of lipopolysaccharide in opsonization and phagocytosis of *Pseudomonas aeruginosa*. *Infect Immun*. 1985; 49:182–189. [PubMed: 3924827]
- Feingold DS, Goldman JN, Kuritz HM. Locus of the action of serum and the role of lysozyme in the serum bactericidal reaction. *J Bacteriol*. 1968a; 96:2118–2126. [PubMed: 4972918]
- Feingold DS, Goldman JN, Kuritz HM. Locus of the lethal event in the serum bactericidal reaction. *J Bacteriol*. 1968b; 96:2127–2131. [PubMed: 4881704]
- Ferrer NL, Gomez AB, Neyrolles O, Gicquel B, Martin C. Interactions of attenuated *Mycobacterium tuberculosis phoP* mutant with human macrophages. *PLoS ONE*. 2010; 5:e12978. [PubMed: 20885976]

- Friedman L, Kolter R. Two genetic loci produce distinct carbohydrate-rich structural components of the *Pseudomonas aeruginosa* biofilm matrix. *J Bacteriol.* 2004; 186:4457–4465. [PubMed: 15231777]
- Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET. O antigen protects *Bordetella parapertussis* from complement. *Infect Immun.* 2008; 76:1774–1780. [PubMed: 18285500]
- Goldman JN, Ruddy S, Austen KF, Feingold DS. The serum bactericidal reaction. 3. Antibody and complement requirements for killing a rough *Escherichia coli*. *J Immunol.* 1969; 102:1379–1387. [PubMed: 4891549]
- Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, Drayson MT, MacLennan CA. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal *Salmonella* by blood cells in Africans. *Proc Natl Acad Sci USA.* 2010; 107:3070–3075. [PubMed: 20133627]
- Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Microbiol Rev.* 1996; 60:539–574. [PubMed: 8840786]
- Gross GN, Rehm SR, Pierce AK. The effect of complement depletion on lung clearance of bacteria. *J Clin Invest.* 1978; 62:373–378. [PubMed: 27534]
- Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. *Infect Immun.* 1983; 42:170–177. [PubMed: 6413410]
- Heale JP, Pollard AJ, Stokes RW, Simpson D, Tsang A, Massing B, Speert DP. Two distinct receptors mediate nonopsonic phagocytosis of different strains of *Pseudomonas aeruginosa*. *J Infect Dis.* 2001; 183:1214–1220. [PubMed: 11262203]
- Iida K, Whitlow MB, Nussenzweig V. Amastigotes of *Trypanosoma cruzi* escape destruction by the terminal complement components. *J Exp Med.* 1989; 169:881–891. [PubMed: 2494292]
- Inoue K, Yonemasu K. Studies on the third component (C'3) of guinea pig complement. II. Decay and generation of SAC' 1a,4,2a,3. *Biken J.* 1968; 11:181–191. [PubMed: 5720343]
- Jackson KD, Starkey M, Kremer S, Parsek MR, Wozniak DJ. Identification of *psl*, a locus encoding a potential exopolysaccharide that is essential for *Pseudomonas aeruginosa* PAO1 biofilm formation. *J Bacteriol.* 2004; 186:4466–4475. [PubMed: 15231778]
- Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB, et al. Compromised host defense on *Pseudomonas aeruginosa* biofilms: characterization of neutrophil and biofilm interactions. *J Immunol.* 2003; 171:4329–4339. [PubMed: 14530358]
- Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH, Dourmashkin R, Frank MM. Multimeric complement component C9 is necessary for killing of *Escherichia coli* J5 by terminal attack complex C5b-9. *Proc Natl Acad Sci USA.* 1985; 82:4808–4812. [PubMed: 3895225]
- Kampen AH, Tollersrud T, Lund A. *Staphylococcus aureus* capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils *in vitro*. *Infect Immun.* 2005; 73:1578–1583. [PubMed: 15731056]
- Kanegasaki S. Studies on phagocyte response to bacteria: conditions for efficient interaction and mechanism of oxygen radical production. *Tokai J Exp Clin Med.* 1986; 11(Suppl):97–102. [PubMed: 2837839]
- Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular antibodies induce type-specific phagocytosis of capsulated *Staphylococcus aureus* by human polymorphonuclear leukocytes. *Infect Immun.* 1988; 56:1090–1095. [PubMed: 3356460]
- Kolb WP, Haxby JA, Arroyave CM, Muller-Eberhard HJ. Molecular analysis of the membrane attack mechanism of complement. *J Exp Med.* 1972; 135:549–566. [PubMed: 5058233]
- Kondos SC, Hatfaludi T, Voskoboinik I, Trapani JA, Law RH, Whisstock JC, Dunstone MA. The structure and function of mammalian membrane-attack complex/perforin-like proteins. *Tissue Antigens.* 2010; 76:341–351. [PubMed: 20860583]
- Learn DB, Brestel EP, Seetharama S. Hypochlorite scavenging by *Pseudomonas aeruginosa* alginate. *Infect Immun.* 1987; 55:1813–1818. [PubMed: 3038752]
- Leid JG, Willson CJ, Shirliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects *Pseudomonas aeruginosa* biofilm bacteria from IFN-gamma-mediated macrophage killing. *J Immunol.* 2005; 175:7512–7518. [PubMed: 16301659]

- Longhi C, Conte MP, Penta M, Cossu A, Antonini G, Superti F, Seganti L. Lactoferricin influences early events of *Listeria monocytogenes* infection in THP-1 human macrophages. *J Med Microbiol.* 2004; 53:87–91. [PubMed: 14729926]
- van Lookeren Campagne M, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. *Cell Microbiol.* 2007; 9:2095–2102. [PubMed: 17590164]
- Lorenzen DR, Gunther D, Pandit J, Rudel T, Brandt E, Meyer TF. *Neisseria gonorrhoeae* porin modifies the oxidative burst of human professional phagocytes. *Infect Immun.* 2000; 68:6215–6222. [PubMed: 11035728]
- Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. *Clin Microbiol Rev.* 2002; 15:194–222. [PubMed: 11932230]
- Ma L, Jackson KD, Landry RM, Parsek MR, Wozniak DJ. Analysis of *Pseudomonas aeruginosa* conditional *psl* variants reveals roles for the *psl* polysaccharide in adhesion and maintaining biofilm structure postattachment. *J Bacteriol.* 2006; 188:8213–8221. [PubMed: 16980452]
- Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ. Assembly and development of the *Pseudomonas aeruginosa* biofilm matrix. *PLoS Pathog.* 2009; 5:e1000354. [PubMed: 19325879]
- Mai GT, Seow WK, Pier GB, McCormack JG, Thong YH. Suppression of lymphocyte and neutrophil functions by *Pseudomonas aeruginosa* mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. *Infect Immun.* 1993; 61:559–564. [PubMed: 8423085]
- Matsukawa M, Greenberg EP. Putative exopolysaccharide synthesis genes influence *Pseudomonas aeruginosa* biofilm development. *J Bacteriol.* 2004; 186:4449–4456. [PubMed: 15231776]
- Mohapatra NP, Soni S, Rajaram MV, Dang PM, Reilly TJ, El-Benna J, et al. Francisella acid phosphatases inactivate the NADPH oxidase in human phagocytes. *J Immunol.* 2010; 184:5141–5150. [PubMed: 20348422]
- Mueller-Ortiz SL, Drouin SM, Wetsel RA. The alternative activation pathway and complement component C3 are critical for a protective immune response against *Pseudomonas aeruginosa* in a murine model of pneumonia. *Infect Immun.* 2004; 72:2899–2906. [PubMed: 15102802]
- Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. *Immunol Rev.* 2007; 219:88–102. [PubMed: 17850484]
- Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. *J Exp Med.* 1980; 152:1102–1114. [PubMed: 6903192]
- Pedersen SS, Kharazmi A, Espersen F, Hoiby N. *Pseudomonas aeruginosa* alginate in cystic fibrosis sputum and the inflammatory response. *Infect Immun.* 1990; 58:3363–3368. [PubMed: 2401567]
- Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. *Microbes Infect.* 2003; 5:1307–1315. [PubMed: 14613774]
- Saldias MS, Ortega X, Valvano MA. *Burkholderia cenocepacia* O antigen lipopolysaccharide prevents phagocytosis by macrophages and adhesion to epithelial cells. *J Med Microbiol.* 2009; 58:1542–1548. [PubMed: 19713359]
- Schreiber RD, Morrison DC, Podack ER, Muller-Eberhard HJ. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. *J Exp Med.* 1979; 149:870–882. [PubMed: 372483]
- Speert DP, Wright SD, Silverstein SC, Mah B. Functional characterization of macrophage receptors for *in vitro* phagocytosis of unopsonized *Pseudomonas aeruginosa*. *J Clin Invest.* 1988; 82:872–879. [PubMed: 3138287]
- Thakker M, Park JS, Carey V, Lee JC. *Staphylococcus aureus* serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. *Infect Immun.* 1998; 66:5183–5189. [PubMed: 9784520]
- Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, et al. Enhanced *Pseudomonas aeruginosa* biofilm development mediated by human neutrophils. *Infect Immun.* 2005; 73:3693–3701. [PubMed: 15908399]
- Wolfgang MC, Kulasekara BR, Liang X, Boyd D, Wu K, Yang Q, et al. Conservation of genome content and virulence determinants among clinical and environmental isolates of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci USA.* 2003; 100:8484–8489. [PubMed: 12815109]




**Fig. 1.**

Serum opsonization of a Psl-deficient mutant of *P. aeruginosa* increases the oxidative burst by human neutrophils. A. Immunoblot showing expression of Psl from EPS extracts derived from strains PAO1, WFP800 and WFP801 (Byrd *et al.*, 2009). These extracts were blotted on a nitrocellulose membrane, probed with anti-Psl antiserum and detected by chemiluminescence using a HRP-conjugated secondary antibody. B. Kinetic analysis of the chemiluminescence response (measurement of oxidative burst) of neutrophils generated against pre-opsonized Psl variant strains of *P. aeruginosa*. Each experiment was performed in quadruplet wells ( $n = 3$  with 10% fresh normal human serum opsonization). RLU, relative


luminescence unit. C. Oxidative burst response of neutrophils induced by Psl variant strains of *P. aeruginosa* under fresh serum opsonized (NHS), heat-inactivated serum (HIS)-opsonized and non-opsonized conditions. Bacteria were incubated with serum or no serum, washed and then incubated with neutrophils (moi 50:1) at 37°C for 25 min in presence of luminol and the chemiluminescence response of neutrophils was measured. Each experiment was performed in quadruplet wells ( $n = 5$  for 10% NHS opsonization, HIS opsonization and non-opsonization). Values are mean  $\pm$  SEM for five experiments. A statistical analysis was carried out using an unpaired two-tailed student's *t*-test to compare the chemiluminescence response of neutrophils induced by HIS, opsonized and unopsonized bacteria. The asterisks indicate *P*-values (\**P* 0.05; \*\**P* 0.005). RLU, relative luminescence unit.






**Fig. 2.**


The presence of Psl reduces the uptake of *P. aeruginosa* by human phagocytic cells. Immunofluorescence images of (A) THP-1 cells and (B) human neutrophils, infected with pre-opsionized WT or a *psI*-deficient strain of *P. aeruginosa*. Bacteria were incubated with neutrophils at an moi of 5:1 and processed as described in *Experimental procedures*. Attached bacteria exposed to the antibodies before permeabilization stained green. Those exposed to the antibodies only after permeabilization stained red (internalized bacteria). Blue (DAPI) fluorescence was used to stain the nuclei of THP-1 cells and neutrophils (60 $\times$  oil objective). Arrows indicate the internalized bacteria in the PAO1 samples. Scale bar is equal to 10  $\mu$ m. The number (mean  $\pm$  SD) of internalized bacteria is indicated in parentheses and is representative of 100 infected cells (neutrophils and macrophages) examined from triplicate coverslips.

**Fig. 3.**

Increased C3 complement component deposition on *psl*-deficient *P. aeruginosa*. A total of  $2 \times 10^8$  mid-log phase bacteria were opsonized with 20% fresh human serum at 37°C for 5 or 20 min, followed by the addition of 10 mM EDTA to stop the reaction. Bacteria were fixed and stained with anti-human C3 antibody (A) counter stained with fluorescent antibody and analysed by flow cytometry (B) counter stained with 15-nm colloidal gold rabbit anti-goat antibody and analysed by transmission electron microscopy (TEM), as outlined in *Experimental procedures*. Bar represents 500 nm. Arrows indicate the C3 complement deposition on the bacterial surface. The number in parentheses (mean  $\pm$  SD) indicated deposition of C3 complement component on individual bacteria (averaged from 100 bacterial cells evaluated). Statistical analysis was carried out using the unpaired two-tailed Student's *t*-test to compare the deposition of C3 complement component on the surface of the *psl*-deficient strain with WT and the Psl<sup>++</sup> strains of *P. aeruginosa*. Mean  $\pm$  SEM are given ( $n = 3$ ). The asterisks indicate *P*-values (\**P* 0.05; \*\**P* 0.005; \*\*\**P* 0.0005).



**Fig. 4.** Psl limits C5 and C7 complement component deposition on *P. aeruginosa*. A total of  $2 \times 10^8$  mid-log phase bacteria were opsonized with 20% fresh human serum at 37°C for 5 and 20 min, followed by the addition of 10 mM EDTA to stop the reaction. Bacteria were fixed and stained with (A) anti-human C5 antibody and (B) anti-human C7 antibody as outlined in *Experimental procedures*. Mean  $\pm$  SEM are given ( $n = 3$ ). Statistical analysis was carried out using the unpaired two-tailed Student's *t*-test to compare the deposition of C3 complement component on the surface of the *psI*-deficient strain with WT and the  $Psl^{++}$  strains of *P. aeruginosa*. The asterisks indicate *P*-values (\*\**P* 0.005; \*\*\**P* 0.0005).




**Fig. 5.**

Psl polysaccharide has no effect on C9 deposition and complement-mediated killing.

A. C9 complement component deposition was measured on WT, *psI*-deficient and Psl overexpressing strains of *P. aeruginosa*. Results are expressed as percentage of fluorescence positive cells as in Fig. 4, which is indicative of complement deposition on the bacterial surface. The experiment shown is representative of three independent experiments performed in triplicate. Data are mean  $\pm$  SEM.


B. Sensitivity of WT, *psI*-deficient and Psl overexpressing strains of *P. aeruginosa* to complement-mediated killing in the presence of 0, 20 and 50 percent fresh normal human serum (NHS). Bacterial survival is expressed as the percentage of bacteria recovered from the initial inoculation amount (incubated with buffer only without serum), which is set at 100%. Data represent mean  $\pm$  SEM from a representative experiment ( $n = 3$ ).

**Fig. 6.**

Psl enhances intracellular survival of *P. aeruginosa* in human neutrophils.

A. Opsonized WT PAO1 and *psl*-deficient *P. aeruginosa* were incubated with  $2 \times 10^5$  human neutrophils at the indicated moi for 30 min. Extracellular and attached bacteria were killed by treatment with gentamicin, then neutrophils were lysed with 0.1% Triton X-100 and lysates plated to enumerate viable bacteria. Results are expressed as the percentage of bacteria that survived relative to total cell-associated bacteria and are representative of three independent experiments performed in triplicate. Bars represent mean  $\pm$  SEM. Statistical analysis was carried out using the unpaired two-tailed Student's *t*-test. The asterisks indicate *P*-values (\*\**P* 0.005; \*\*\**P* 0.0005).

B. Immunofluorescence images (60× oil objective) showing equal uptake of bacteria (stained red) by neutrophils when the moi of WT and *psl*-deficient bacteria were adjusted. The moi and number of internalized bacteria (mean ± SD) per 100 neutrophils are indicated. Colours indicate: green, attached bacteria; red, internalized bacteria; blue, neutrophil nucleus. Scale bar represent 10 μm.



**Fig. 7.**

The presence of Psl provides a fitness advantage for *P. aeruginosa* during an acute murine pulmonary infection. Six-week-old female C57BL/6 mice were co-infected at a 1:1 ratio (total of  $10^8$  bacteria) with *psl* mutant and WT streptomycin resistant *P. aeruginosa* strains. Bacteria were harvested from the lungs at 4 and 12 h post infection. Viable cell counts and the competitive index (CI) of the two strains were determined as outlined in the *Experimental procedures*. Dashed line represents a CI of 1.0 (no advantage for WT or *psl* mutants).